Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Surprises with a 5% Q1 Revenue Increase

publication date: May 15, 2009

WuXi PharmaTech (药明康德) announced a 5% increase in Q1 revenues, but net income fell 15% and earnings per share dropped an even-greater 22% during the period. Stressing the positive, WuXi said its core business, China CRO laboratory services, rose a healthy 33%. The problem was in contract manufacturing, whose revenues sank by 81%. Evidently, WuXi has done a good job of preparing Wall Street for even worse results, because shares of WuXi moved sharply higher following the earnings announcement. More details...

Stock Symbol: (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital